The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Validation Of A Multiplexed Blood Based Screening Assay For The Diagnosis Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$556,712.00
Summary
Colorectal cancer (CRC) is the second most common cancer in Australia with poor patient outcome due to late detection of the disease. We have developed a simple blood based test that can diagnose individuals with CRC at an early stage when the chance of cure is greater than 80%.
Developing A Prototype Of A Next Generation Brain Computer Interface
Funder
National Health and Medical Research Council
Funding Amount
$837,398.00
Summary
Persons affected by quadriplegia and hemiplegia from stroke and spinal cord injury have few treatment options. Brain Machine Interfaces reconnect brain to a prosthetic limb, bypassing damaged nervous system. Our group has developed a BMI that can be implanted minimally-invasively, inside a blood vessel in the brain. We propose to manufacture a world-first device for a human clinical trial pilot study. The aim is to restore mechanical control over the physical environment for a paralysed patient.
Humanisation And Pre-clinical Validation Of A Therapeutic Anti-cancer Antibody
Funder
National Health and Medical Research Council
Funding Amount
$699,136.00
Summary
This grant will develop a novel antibody against a protease expressed on cancer cells. Preclinical studies, and antibody humanisation, will be performed. This project will also provide vital information on optimal therapeutic approaches with the antibody that can be ultimately taken into human trials.
Single Shot X-ray Tomography For Real-Time Functional X-ray Imaging
Funder
National Health and Medical Research Council
Funding Amount
$322,641.00
Summary
Computed Tomography (CT) scanners produce three-dimensional images of vital organs that cannot be obtained by conventional two-dimensional (single projection) x-ray radiographs. However, the radiation exposure is hundreds of times higher than conventional radiography. We will develop the world’s first CT scanner that uses no more radiation than a single conventional x-ray image that will provide four-dimensional reconstructions of a patient’s moving internal organs.
Improving Oocyte Mitochondrial DNA Copy Number To Enhance Female Reproductive Capacity.
Funder
National Health and Medical Research Council
Funding Amount
$670,867.00
Summary
Eggs with too few copies of mitochondrial DNA either fail to fertilise or arrest during early development. By supplementing eggs with mitochondrial DNA, we have been able to enhance embryo quality and gene expression profiles. By breeding the offspring derived from eggs given mitochondrial supplementation, we will determine if they and their progeny meet normal developmental milestones, regulate the transmission of mitochondrial DNA appropriately, and are healthy and fertile.
Development Of A High Acuity, Diamond Retinal Prosthesis
Funder
National Health and Medical Research Council
Funding Amount
$1,010,214.00
Summary
Over recent years our team has developed a retinal implant to restore sight to people with certain types of blindness. With 256 independently controllable electrodes this device is among the most sophisticated in the world. We aim to conduct experiments to demonstrate that our device can provide improved better visual acuity than the world leaders with a view to developing a competitive commercial medical technology.
Multidrug Resistance Protein 1 Inhibitors To Sensitise Cancers To Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$840,166.00
Summary
Multidrug resistance protein 1 (MRP1) is often present at high levels in cancer cells, where it pumps chemotherapy drugs back out, causing drug resistance. Inhibitors that block MRP1 would increase the effectiveness of chemotherapy. We have developed MRP1 inhibitors with promising activity in cancer cells and mouse tumours and will now develop these inhibitors for clinical application and commercialisation.
Harnessing Anticalin Technology As A Multi-targeted Treament Approach For Vision Loss
Funder
National Health and Medical Research Council
Funding Amount
$627,273.00
Summary
Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.
We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
Interactive Attention Training Technology To Enhance Cognitive Skills In Early Life
Funder
National Health and Medical Research Council
Funding Amount
$759,680.00
Summary
Over 30,000 Australian children enter school with attention difficulties each year. We have established a suite of tasks to train attention based on over 20 years of research into neurodevelopmental disorders and attention. These are delivered on tablets in the form of a game known as TALI Train. We now aim to show TALI can improve attention in children with acquired brain injuries and typically developing children for commercialisation to a broad market.